December 5, 2014
Asahi Kasei Pharma said on December 3 that the company entered into a license agreement with South Korean drug maker Dong-A ST on October 1 for exclusive rights to develop and sell its osteoporosis treatment Teribone (teriparatide) in South Korea...read more